Cargando…

Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?

Detalles Bibliográficos
Autores principales:	Derosa, Lisa, Zitvogel, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106675/ https://www.ncbi.nlm.nih.gov/pubmed/33966043 http://dx.doi.org/10.1038/s41392-021-00585-5

Ejemplares similares

90. Fecal Microbiota Transplantation in Metastatic Melanoma Patients Resistant to Anti-PD-1 Treatment
por: Youngster, Ilan, et al.
Publicado: (2019)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

A role for complement blockade in kidney transplantation
por: Karpman, Diana, et al.
Publicado: (2022)

Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade
por: Li, Xue, et al.
Publicado: (2019)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014)

Fecal Microbiota Transplant in Immunotherapy-Resistant Melanoma: What Can We Expect in the Near Future?
por: Ferreira, André, et al.
Publicado: (2022)

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer
por: Mi, Mi, et al.
Publicado: (2022)

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
por: Fortman, Dylan, et al.
Publicado: (2023)

Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review
por: BARBOSA, EDUARDO CERCHI, et al.
Publicado: (2023)

The intimate relationship between gut microbiota and cancer immunotherapy
por: Elkrief, Arielle, et al.
Publicado: (2018)

A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota
por: Messaoudene, Meriem, et al.
Publicado: (2022)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

Gut microbiota: in sickness and in health
por: Huertas, M José, et al.
Publicado: (2014)

Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling
por: Fidelle, Marine, et al.
Publicado: (2023)

Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
por: Safinia, Niloufar, et al.
Publicado: (2021)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Hypothesis: Unrecognized actions of ENaC blockade in improving refractory-resistant hypertension and residual cardiovascular risk
por: Elijovich, Fernando, et al.
Publicado: (2020)

Cold is cool, the human microbiota and taking multiple SIPs
por: Daniels, Craig, et al.
Publicado: (2011)

The microbiota–gut–brain axis regulates motivation for exercise
por: Sun, Wenhuan, et al.
Publicado: (2023)

Collaborative impact of bacterial exometabolites governing root microbiota formation
por: Kareem, Hafiz Abdul, et al.
Publicado: (2023)

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade
por: Ferrere, Gladys, et al.
Publicado: (2021)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Reply to ‘Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma’
por: Jacquelot, Nicolas, et al.
Publicado: (2018)

Intestinal homeostasis and inflammation: Gut microbiota at the crossroads of pancreas–intestinal barrier axis
por: Zhang, Zhongwei, et al.
Publicado: (2022)

First stem cell transplantation to regenerate human lung
por: Wang, Si, et al.
Publicado: (2018)

Can fecal microbiota transplantation cure irritable bowel syndrome?
por: Halkjær, Sofie Ingdam, et al.
Publicado: (2017)

A P4 Medicine Perspective of Gut Microbiota and Prediabetes: Systems Analysis and Personalized Intervention
por: Huang, Qiongrong, et al.
Publicado: (2020)

Can cannibalizing cancer cells challenge classic cell death classification?
por: Walton, Emma Louise
Publicado: (2017)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
por: Zhang, Guanyi, et al.
Publicado: (2015)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

The emerging roles of transplanted radial glial cells in regenerating the central nervous system
por: White, Robin E., et al.
Publicado: (2015)

High response rate to PD-1 blockade in desmoplastic melanomas
por: Eroglu, Zeynep, et al.
Publicado: (2018)

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
por: Amante, Romain J., et al.
Publicado: (2023)

Modification of the susceptibility gene TaPsIPK1 - a win-win for wheat disease resistance and yield
por: Macho, Alberto, et al.
Publicado: (2022)

Fecal Microbiota Transplantation: Is It Safe?
por: Park, Seon-Young, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rfnt3l4au6ougg6venm4sjc59m